[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Eli Lilly, Home Depot & SAP",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.",
    "url": "https://finnhub.io/api/news?id=5477590ac46f365419c5d285f033a64541546d23fc5c51d1d388e2b791b9d0e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749846660,
      "headline": "Top Analyst Reports for Eli Lilly, Home Depot & SAP",
      "id": 135257533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.",
      "url": "https://finnhub.io/api/news?id=5477590ac46f365419c5d285f033a64541546d23fc5c51d1d388e2b791b9d0e8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial",
    "summary": "Eli Lilly's experimentalobesity drug, eloralintide, helped some patients lose 11.5% oftheir body weight at 12 weeks in an early-stage study, aninvestor note by brokerage Cantor Fitzgerald showed on...",
    "url": "https://finnhub.io/api/news?id=9b6649184068fd917ba3c044f6040421e8ca4e27c74f344e7f25f42bb24ab017",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749839951,
      "headline": "Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial",
      "id": 135257486,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly's experimentalobesity drug, eloralintide, helped some patients lose 11.5% oftheir body weight at 12 weeks in an early-stage study, aninvestor note by brokerage Cantor Fitzgerald showed on...",
      "url": "https://finnhub.io/api/news?id=9b6649184068fd917ba3c044f6040421e8ca4e27c74f344e7f25f42bb24ab017"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Europe’s Most Valuable Company—Again. Eli Lilly, Watch Out.",
    "summary": "Novo Nordisk  the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company after a year of decline that ultimately led to the firing of its CEO last month.  Novo’s market capitalization is now $367 billion, pushing it above German software giant  SAP’s  $363 billion.  On Friday, Novo stock was up as much as 2% in Denmark.",
    "url": "https://finnhub.io/api/news?id=03e78fcd680b385a3f0c6a472ce9a37d2755626da304fc450780e7d7fb1116cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749833880,
      "headline": "Novo Nordisk Is Europe’s Most Valuable Company—Again. Eli Lilly, Watch Out.",
      "id": 135255233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk  the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company after a year of decline that ultimately led to the firing of its CEO last month.  Novo’s market capitalization is now $367 billion, pushing it above German software giant  SAP’s  $363 billion.  On Friday, Novo stock was up as much as 2% in Denmark.",
      "url": "https://finnhub.io/api/news?id=03e78fcd680b385a3f0c6a472ce9a37d2755626da304fc450780e7d7fb1116cd"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?",
    "summary": "LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?",
    "url": "https://finnhub.io/api/news?id=09e700b07be8908c0de258ebf731a19a051f7999353a18f3b65996410d72e1e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749825660,
      "headline": "Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?",
      "id": 135253143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?",
      "url": "https://finnhub.io/api/news?id=09e700b07be8908c0de258ebf731a19a051f7999353a18f3b65996410d72e1e0"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump",
    "summary": "(Bloomberg) -- President Donald Trump’s tariff regime may not be having the desired effect of bringing manufacturing back to the US yet, but it’s making companies sound a lot more patriotic.Most Read from BloombergShuttered NY College Has Alumni Fighting Over Its FutureTrump’s Military Parade Has Washington Bracing for Tanks and WeaponryNYC Renters Brace for Price Hikes After Broker-Fee BanDo World’s Fairs Still Matter?NY Long Island Rail Service Resumes After Grand Central FireAt least that’s w",
    "url": "https://finnhub.io/api/news?id=19ee345f02d5855811a03ce921735841387c1163de93cd579254ad7b56907087",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749823200,
      "headline": "Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump",
      "id": 135248344,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump’s tariff regime may not be having the desired effect of bringing manufacturing back to the US yet, but it’s making companies sound a lot more patriotic.Most Read from BloombergShuttered NY College Has Alumni Fighting Over Its FutureTrump’s Military Parade Has Washington Bracing for Tanks and WeaponryNYC Renters Brace for Price Hikes After Broker-Fee BanDo World’s Fairs Still Matter?NY Long Island Rail Service Resumes After Grand Central FireAt least that’s w",
      "url": "https://finnhub.io/api/news?id=19ee345f02d5855811a03ce921735841387c1163de93cd579254ad7b56907087"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock up on Plans to Advance Obesity Candidate Amycretin",
    "summary": "Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.",
    "url": "https://finnhub.io/api/news?id=37d2fc035881fc33a3b4a453b4f1819c4902a9d08104832928fa2f59f4cfd2f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749820080,
      "headline": "NVO Stock up on Plans to Advance Obesity Candidate Amycretin",
      "id": 135248513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.",
      "url": "https://finnhub.io/api/news?id=37d2fc035881fc33a3b4a453b4f1819c4902a9d08104832928fa2f59f4cfd2f4"
    }
  },
  {
    "ts": null,
    "headline": "Down 12%, Should You Buy the Dip on Eli Lilly?",
    "summary": "Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market.  Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years.  The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years.",
    "url": "https://finnhub.io/api/news?id=ba355189253ab5aec7b3babfbcc38832ea324604c308219e823c9ee832ecd901",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749798600,
      "headline": "Down 12%, Should You Buy the Dip on Eli Lilly?",
      "id": 135248516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market.  Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years.  The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years.",
      "url": "https://finnhub.io/api/news?id=ba355189253ab5aec7b3babfbcc38832ea324604c308219e823c9ee832ecd901"
    }
  },
  {
    "ts": null,
    "headline": "Impax Ellevate Global Women's Leadership Fund Q1 2025 Commentary",
    "summary": "During the first quarter, the Global Womenâs Leadership portfolio lagged global developed market equities overall in the period.",
    "url": "https://finnhub.io/api/news?id=316577c6f240ae7b7ec97c54bca8c839df1a84fa3376c8a75b1ce5259d9bf6e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749791940,
      "headline": "Impax Ellevate Global Women's Leadership Fund Q1 2025 Commentary",
      "id": 135235419,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1342783234/image_1342783234.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "During the first quarter, the Global Womenâs Leadership portfolio lagged global developed market equities overall in the period.",
      "url": "https://finnhub.io/api/news?id=316577c6f240ae7b7ec97c54bca8c839df1a84fa3376c8a75b1ce5259d9bf6e2"
    }
  }
]